We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-2.86%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.1B
AUM Growth
-$432M
Cap. Flow
-$290M
Cap. Flow %
-26.37%
Top 10 Hldgs %
65.53%
Holding
227
New
63
Increased
36
Reduced
51
Closed
66

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$19.5M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$7.96M
3
MNKD icon
MannKind Corp
MNKD
+$4.94M
4
ESPR
Esperion Therapeutics
ESPR
+$3.17M
5
BNBX
BNB PLUS CORP
BNBX
+$2.81M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.35M
2
BMY icon
Bristol-Myers Squibb
BMY
+$3.2M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$2.96M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$2.32M
5
HURA
TuHURA Biosciences
HURA
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 11.87%
2 Financials 0.19%
3 Industrials 0.07%
4 Consumer Staples 0.03%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
PUT
Bristol-Myers Squibb
BMY
$130B
$213M 19.36%
34,682
+1,613
+5% +$101K
MRK icon
2
CALL
Merck
MRK
$326B
$103M 9.34%
19,097
-27,161
-59% -$1.51M
BLUE
3
CALL
DELISTED
bluebird bio
BLUE
$75.7M 6.89%
328
+25
+8% +$50.8K
OEF icon
4
CALL
iShares S&P 100 ETF
OEF
$19.8B
$64.1M 5.84%
+4,205
New +$485K
BMY icon
5
Bristol-Myers Squibb
BMY
$130B
$57.1M 5.2%
931,807
-51,148
-5% -$3.2M
SPY icon
6
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$53.6M 4.88%
+3,000
New +$780K
AZN icon
7
CALL
AstraZeneca
AZN
$267B
$51.9M 4.72%
7,473
+5,228
+233% +$353K
SRPT icon
8
CALL
Sarepta Therapeutics
SRPT
$1.63B
$50.2M 4.57%
9,023
+1,760
+24% +$93.2K
AZN icon
9
PUT
AstraZeneca
AZN
$267B
$26.1M 2.37%
3,756
+2,734
+268% +$184K
BMY icon
10
CALL
Bristol-Myers Squibb
BMY
$130B
$25.9M 2.36%
4,225
-5
-0.1% -$313
ODT
11
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$20.6M 1.88%
+825,451
New +$19.5M
ALNY icon
12
PUT
Alnylam Pharmaceuticals
ALNY
$38.5B
$20.4M 1.85%
1,603
-1,562
-49% -$196K
FOLD
13
CALL
DELISTED
Amicus Therapeutics
FOLD
$14.9M 1.36%
10,371
+6,233
+151% +$85.6K
MRK icon
14
PUT
Merck
MRK
$326B
$14.9M 1.36%
2,779
-1,601
-37% -$88.8K
VRTX icon
15
CALL
Vertex Pharmaceuticals
VRTX
$124B
$13.8M 1.25%
919
-1,946
-68% -$288K
JUNO
16
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$13.7M 1.25%
+3,003
New +$150K
CI icon
17
CALL
Cigna
CI
$79.6B
$13.6M 1.24%
670
– –
ZGNX
18
CALL
DELISTED
Zogenix, Inc.
ZGNX
$12.4M 1.13%
3,090
-1,775
-36% -$68.2K
ALNY icon
19
CALL
Alnylam Pharmaceuticals
ALNY
$38.5B
$12M 1.09%
941
-3,739
-80% -$470K
ESPR
20
PUT
DELISTED
Esperion Therapeutics
ESPR
$11M 1%
1,670
+191
+13% +$10.3K
HALO icon
21
CALL
Halozyme
HALO
$9.9B
$10M 0.91%
4,950
-8,087
-62% -$149K
SGMO
22
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9.91M 0.9%
6,040
+2,056
+52% +$30.6K
INCY icon
23
PUT
Incyte
INCY
$26B
$9.81M 0.89%
1,036
+852
+463% +$89.1K
ESPR
24
DELISTED
Esperion Therapeutics
ESPR
$9.36M 0.85%
142,185
+58,828
+71% +$3.17M
ALKS icon
25
CALL
Alkermes
ALKS
$8.42B
$8.75M 0.8%
+1,599
New +$81.6K
1
2 3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sabby Management held 227 positions worth $1.1B, down 28% from $1.53B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $290M in Q4 2017, closing 66 positions and reducing 51 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $3.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 7.3% a quarter earlier, followed by Financials and Industrials.

Against the trend, Sabby Management opened a new position in Odonate Therapeutics, Inc. Common Stock worth $20.6M.

  • Sabby Management's largest Q4 2017 buy was Odonate Therapeutics, Inc. Common Stock: 825,451 shares worth $20.6M.
  • Sabby Management added most to Esperion Therapeutics in Q4 2017, an estimated $3.17M increase.
  • Sabby Management's biggest Q4 2017 reduction was Bristol-Myers Squibb, cutting an estimated $3.2M.
  • Sabby Management fully exited GW Pharmaceuticals Plc American Depositary Shares in Q4 2017, selling an estimated $3.35M.
  • Sabby Management's ten largest holdings make up 66% of its $1.1B portfolio in Q4 2017.
  • Sabby Management opened 63 new positions and closed 66 in Q4 2017.
  • Sabby Management's portfolio value fell 28% quarter-over-quarter to $1.1B.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.